MSGID: 1:317/3 6279eaa6   
   PID: hpt/lnx 1.9.0-cur 2019-01-08   
   TID: hpt/lnx 1.9.0-cur 2019-01-08   
    Major discovery provides new hope for blood cancer patients    
      
     Date:   
         May 9, 2022   
     Source:   
         University of South Australia   
     Summary:   
         Acute myeloid leukaemia is a rare and devastating blood cancer that   
         is highly resistant to treatment. Now, scientists have discovered   
         a way to suppress a specific protein that promotes drug resistance.   
      
      
      
   FULL STORY   
   ==========================================================================   
   South Australian scientists have made a significant breakthrough in   
   overcoming drug resistance in acute myeloid leukemia (AML), a rare and   
   devastating blood cancer that kills most patients within a few years.   
      
      
   ==========================================================================   
   In a new study published in the world-leading hematology journal Blood,   
   researchers from the University of South Australia and SA Pathology's   
   Centre for Cancer Biology describe how they have discovered a way to   
   suppress a specific protein that promotes resistance to drugs commonly   
   used to treat AML patients.   
      
   Professor Stuart Pitson, one of the lead authors of the study, says   
   the finding could revolutionise the treatment of AML, a disease that   
   has claimed the lives of Australian football great Russell Ebert,   
   professional golfer Jarrod Lyle, high-profile American journalist Nora   
   Ephron and filmmaker Lynn Shelton.   
      
   This year, it is estimated that 20,000 people in the United States and   
   900 people in Australia will be diagnosed with acute myeloid leukemia,   
   a cancer of the blood and bone marrow characterised by an overproduction   
   of cancerous white blood cells called leukaemic blasts.   
      
   Prof Pitson says these cells crowd out normal white blood cells, which   
   then can't do their usual infection-fighting work, thereby increasing   
   the risk of infections, low oxygen levels and bleeding.   
      
   SA Pathology haematologist Associate Professor David Ross says many AML   
   patients initially respond to Venetoclax, a new therapy for AML recently   
   listed on the PBS, but over time AML cells become resistant to it.   
      
      
      
   ==========================================================================   
   Using a large biobank of patient-donated AML biopsies and world-leading   
   advanced pre-clinical models, the CCB researchers demonstrated that   
   by modulating lipid metabolism in the body, a protein called Mcl-1 is   
   inhibited in AML cells -- the protein that facilitates drug resistance.   
      
   "This process makes AML cells exquisitely sensitive to Venetoclax,   
   while leaving the normal white blood cells unaffected," SA Pathology   
   researcher and co-lead author, Associate Professor Jason Powell says.   
      
   The CCB team is now working hard to optimise drugs targeting this pathway   
   to take into clinical trials for AML patients.   
      
   "For most people with AML, the chances of long-term survival are no   
   better now than they were last century," Assoc Prof Ross says.   
      
   "Now, we have a chance to remedy that. New treatments that prevent   
   Venetoclax resistance have the potential to prolong survival, or even   
   increase the chances of a cure in a disease for which improved outcomes   
   are desperately needed."  Background   
      
      
   ==========================================================================   
   Acute myeloid leukemia (AML) accounts for approximately 0.8 per cent of   
   all cancers diagnosed, at a rate of 3.7 per 100,000 people. It can occur   
   at any age but is more common in adults (and men) over the age of 60.   
      
   In most cases the causes remain unknown, but it is thought to result from   
   damage to one of more genes that normally control blood cell development.   
      
   Current therapies are effective at putting patients into remission, but   
   relapse is common, with fewer than 30 per cent of AML patients surviving   
   five years post diagnosis.   
      
   In 1990, acute myeloid leukemia (AML) accounted for 18.0% of the total   
   leukemia cases worldwide. This proportion increased to 23.1% in 2017.   
      
      
   ==========================================================================   
   Story Source: Materials provided by University_of_South_Australia. Note:   
   Content may be edited for style and length.   
      
      
   ==========================================================================   
   Journal Reference:   
      1. Alexander C Lewis, Victoria S Pope, Melinda N Tea, Manjun Li, Gus O   
         Nwosu, Thao M Nguyen, Craig Thomas Wallington-Beddoe, Paul A   
         Moretti, Dovile Anderson, Darren J Creek, Maurizio Costabile,   
         Saira R Ali, Chloe AL Thompson-Peach, B Kate Dredge, Andrew G Bert,   
         Gregory J Goodall, Paul G Ekert, Anna L Brown, Richard J D'Andrea,   
         Nirmal Robinson, Melissa R Pitman, Daniel Thomas, David M Ross,   
         Briony L Gliddon, Jason A Powell, Stuart M Pitson. Ceramide-induced   
         integrated stress response overcomes Bcl-2 inhibitor resistance in   
         acute myeloid leukemia. Blood, 2022; DOI: 10.1182/blood.2021013277   
   ==========================================================================   
      
   Link to news story:   
   https://www.sciencedaily.com/releases/2022/05/220509100940.htm   
      
   --- up 10 weeks, 10 hours, 50 minutes   
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)   
   SEEN-BY: 15/0 106/201 114/705 123/120 129/330 331 153/7715 218/700   
   SEEN-BY: 229/110 111 112 317 400 426 428 470 664 700 292/854 298/25   
   SEEN-BY: 305/3 317/3 320/219 396/45   
   PATH: 317/3 229/426